Akt/pbotein kinace B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation

Cancer Research

Volumn 61, Issue 10, 2001, Pages 3986-3997

  Brognard, J ^a   Clark, A S ^a   Ni, Y ^a   Dennis, P A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ETOPOSIDE; GEMCITABINE; PACLITAXEL; PROTEIN KINASE B; TRASTUZUMAB; WORTMANNIN; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; AKT1 PROTEIN, HUMAN; CHROMONE DERIVATIVE; ENZYME INHIBITOR; MORPHOLINE DERIVATIVE; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN SERINE THREONINE KINASE;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYME ACTIVATION; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; RADIATION DOSE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; CHROMONES; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; LUNG NEOPLASMS; MORPHOLINES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION TOLERANCE; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0035872199     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (90)

1. Cancer statistics, 1999
2. Chemotherapy-induced apoptosis
3. Effects of chemotherapy on ultrastructure of oesophageal squamous cell carcinoma
4. Apoptotic cell death during treatment of leukemias
5. p53 mutations in human cancers
6. p53 gene mutations are associated with shortened survival in patients with advanced non-small cell lung cancer: An analysis of medically managed patients
7. K-ras genotypes and prognosis in non-small cell lung cancer
8. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers
9. Mechanisms of p16INK4A inactivation in non-small cell lung cancers
10. Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer
11. Prognostic significance of cyclin E overexpression in resected non-small cell lung cancer
12. Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication
13. The expression of basic fibroblast growth factor (bFGF) in tumor- associated stromal cells and vessels is inversely correlated with non-small cell lung cancer progression
14. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma
15. p185neu expression in human lung adenocarcinomas predicts shortened survival
16. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas
17. Expression in lung carcinomas of platelet-derived growth factor and its receptors
18. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor, and angiogenesis in non-small cell lung cancer
19. TGF-β, radiation-induced pulmonary injury, and lung cancer
20. The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors
21. Insulin-like growth factor expression in human cancer cell lines
22. Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk
23. Cellular survival: A play in three Akts
24. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region
25. Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families
26. Molecular cloning and identification of a serine/threonine prodein kinase of the second-messenger subfamily
27. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas
28. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA
29. PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2
30. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase
31. Integrin-linked kinase regulates phosphorylation of serine 473 of protein kinase B by an indirect mechanism
32. Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site
33. Mechanism of protein kinase B activation by cyclic AMP-dependent protein kinase
34. Calcium promotes cell survival through CaM-K kinase activation of the protein-kinase-B pathway
35. 2O2 or heat shock is mediated by phosphoinositide 3-kinase and not by mitogen-activated protein kinase-activated protein kinase-2
36. Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells
37. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
38. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt
39. Regulation of cell death protease caspase-9 by phosphorylation
40. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit
41. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor
42. Direct control of the Forkhead transcription factor AFX by protein kinase B
43. NF-κB activation by tumour necrosis factor requires the Akt serine- threonine kinase
44. NF-κB is a target of AKT in anti-apoptotic PDGF signaling
45. Regulation of neuronal survival by the serine-threonine protein kinase Akt
46. Suppression of c-Myc-induced apoptosis by Ras signaling through PI(3)K and PKB
47. Akt/protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria
48. Matrix adhesion and ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway
49. Anti-apoptotic signaling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt
50. Suppression of transforming growth factor-β-induced apoptosis through a phosphatidylinositol 3-kinase/Akt-dependent pathway
51. Phosphatidylinositol 3-kinase and Akt protein kinase are necessary and sufficient for the survival of nerve growth factor-dependent sympathetic neurons
52. Akt, a target of phosphatidylinositol 3-kinase, inhibits apoptosis in a differentiating neuronal cell line
53. Akt-dependent potentiation of L channels by insulin-like growth factor- 1 is required for neuronal survival
54. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation
55. Protection of CD95-mediated apoptosis by activation of phosphatidylinositide 3-kinase and protein kinase B
56. Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor I
57. The opposing roles of the Akt and c-Myc signaling pathways in survival from CD95-mediated apoptosis
58. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons
59. The bile acid taurochenodeoxycholate activates a phosphatidylinositol 3- kinase-dependent survival signaling cascade
60. 1 cell cycle checkpoint pathway and ataxia- telangiectasia
61. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
62. Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation in esophageal cancer cells
63. Effects of more than one inhibitor
64. Cell culture methods for the establishment of the NCI series of lung cancer cell lines
65. NCI-Navy Medical Oncology Branch Cell Line Data Base
66. Differential phosphorylation at Ser473 and Thr308 of Akt-1 in rat brain following hypoglycemic coma
67. The lipid phosphatase activity of PTEN is critical for its tumor suppressor function
68. Mutation analysis of the PTEN/MMAC1 gene in lung cancer
69. Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers
70. Wortmannin and its structural analogue demethoxyviridin inhibit stimulated phospholipase A2 activity in Swiss 3T3 cells. Wortmannin is not a specific inhibitor of phosphatidylinositol 3-kinase
71. Characterization of a soluble adrenal phosphatidylinositol 4-kinase reveals Wortmannin sensitivity of type III phosphatidylinositol kinases
72. 2-M delay
73. Inhibition of phosphoinositide 3-kinase-related kinases by the radio-sensitizing agent Wortmannin
74. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells
75. Direct inhibition of the signaling functions of the by the phosphoinositide 3-kinase inhibitors, Wortmannin and LY294002
76. Different mechanisms between premitotic apoptosis and postmitotic apoptosis in X-irradiated U937 cells
77. Sphingosine is a novel activator of 3-phosphoinositide-dependent kinase I
78. Oxidative stress and vanadate induce tyrosine phosphorylation of phosphoinositide-dependent kinase 1 (PDK1)
79. Phosphorylation of the PTEN tail regulates protein stability and function
80. Alteration of the PTEN/MMAC1 gene locus in primary lung cancer with distant metastasis
81. Alterations of PTEN/MMAC1, a candidate tumor suppressor gene, and its homologue, PTH2, in small cell lung cancer cell lines
82. PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers
83. The inositol phosphatase SHIP inhibits Akt/PKB activation in B cells
84. SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival
85. Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors
86. Inactivation and dephosphorylation of protein kinase Bα (PKBα) promoted by hyperosmotic stress
87. Alterations of the PPP2R1B gene in human lung and colon cancer
88. Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals
89. The phosphatidylinositol 3-kinase inhibitor Wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage
90. Wortmannin is a potent inhibitor of DNA double-strand break but not single-strand break repair in Chinese hamster ovary cells